Skip to main content
EuBiologics Co., Ltd. logo

EuBiologics Co., Ltd. — Investor Relations & Filings

Ticker · 206650 ISIN · KR7206650004 KO Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2024-09-30 Regulatory Filings
Country KR South Korea
Listing KO 206650

About EuBiologics Co., Ltd.

http://eubiologics.com/eng/

EuBiologics Co., Ltd. is a biopharmaceutical company focused on improving global public health through the development and supply of safe and effective vaccines. The company specializes in preventative vaccines against global pandemics and emerging infectious diseases, with a key product being its oral cholera vaccine. In addition to its vaccine pipeline, EuBiologics provides Contract Research and Manufacturing Organization (CRMO) services. These services cover the development and GMP-compliant production of mammalian cell and microbial-derived biopharmaceuticals, including protein-based therapeutics and antibodies. The company is committed to technological innovation and adhering to international standards to address global health challenges.

Recent filings

Filing Released Lang Actions
본점소재지변경
Regulatory Filings Classification · 100% confidence The document is a short regulatory announcement regarding a change in the company's registered office address (본점소재지변경). It provides specific details such as the old address, new address, reason for the change, and the date of the board resolution. Since this is a standard corporate regulatory disclosure that does not fit into specific categories like financial reports, dividends, or share transactions, it falls under the general regulatory filing category.
2024-09-30 Korean
단일판매ㆍ공급계약체결(자율공시)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Eubiologics) announcing a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결). This is a standard corporate disclosure regarding a specific business contract with UNICEF. Since it does not fit into specific categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2024-09-12 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정) (5가 수막구균 접합백신 EuNmCV5 유엔엠씨브이파이브 멀티주의 제2/3상 아프리카 임상시험계획 승인)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure from Eubiologics regarding the approval of a Phase 2/3 clinical trial for a 5-valent meningococcal conjugate vaccine in The Gambia. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) filings on the KRX (Korea Exchange). Since it details a specific regulatory event (clinical trial approval) and does not fit into categories like financial reports, dividends, or board changes, it is classified as a Regulatory Filing (RNS).
2024-09-03 Korean
단일판매ㆍ공급계약체결(자율공시)
Regulatory Filings Classification · 100% confidence The document is a formal disclosure of a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) by Eubiologics. It details a specific contract with UNICEF for the supply of cholera vaccines. Since this is a specific corporate event disclosure regarding a commercial contract that does not fit into the other specialized categories like M&A or financial reports, it falls under the general regulatory filing category.
2024-08-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard regulatory disclosure for insider transactions or changes in share ownership by company directors/executives. In the provided taxonomy, 'Director's Dealing' (DIRS) is the correct category for reports detailing personal share transactions or ownership changes by company directors and executives.
2024-08-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of an executive (Chae Su Min) at Eubiologics, including specific transaction dates, types (stock options, market sales), and quantities. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2024-08-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.